Streetbeat News

Products Services

SIDU

Sidus Space has announced the sale of its FeatherEdge Onboard Computing System to Xiomas Technologies. This marks a significant milestone for Sidus Space as it expands its customer base and showcases the capabilities of its technology.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:34 pm

GNPX

Genprex has been granted a patent in Singapore for its Reqorsa gene therapy in combination with PD-1 antibodies, extending protection through 2037. This expands on previously granted patents covering the use of REQORSA with immune checkpoint inhibitors.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:33 pm

ADIL

Adial Pharmaceuticals (NASDAQ:ADIL) announced a collaboration with Boudicca Dx to advance the regulatory strategy for its companion diagnostic genetic test for AD04, a treatment for Alcohol Use Disorder. This collaboration aims to ensure the test meets FDA guidelines and supports the upcoming Phase 3 study.

Portfolio Pulse from Vandana Singh

August 13, 2024 | 12:30 pm

ADIL

Adial Pharmaceuticals has signed an agreement with Boudicca Dx to advance the regulatory strategy for a companion diagnostics genetic test for AD04.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:30 pm

NVDA

SOXX

TDIV

TSM

Taiwan Semiconductor Manufacturing Co (NYSE:TSM) is facing a severe workforce crisis that could hinder its AI growth, despite a 45% surge in July sales. The U.S. chip manufacturing workforce has significantly shrunk, and the demand for specialized workers is expected to rise sharply. This shortage could become a major bottleneck for TSM and the broader industry. TSM is a key supplier to Nvidia Corp (NASDAQ:NVDA), and investors can gain exposure through ETFs like iShares Semiconductor ETF (NASDAQ:SOXX) and First Trust NASDAQ Technology Dividend Index Fund (NASDAQ:TDIV).

Portfolio Pulse from Anusuya Lahiri

August 13, 2024 | 12:28 pm

APVO

Aptevo Therapeutics has initiated a Phase 1b/2 RAINIER trial to evaluate its lead candidate Mipletamig (APVO436) in combination with Venetoclax and Azacitidine for frontline acute myeloid leukemia (AML). The new data from this trial is expected to bolster existing efficacy outcomes and identify the recommended Phase 2 dose.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:27 pm

DJT

Trump Media & Technology Group Corp. (NASDAQ:DJT) continues to decline in premarket trading after a significant drop on Monday. The company reported a Q2 loss of $16.4 million and revenue of $837,000. Trump's return to X and the faltering metrics of Truth Social are contributing to the stock's downward pressure.

Portfolio Pulse from Shanthi Rexaline

August 13, 2024 | 12:27 pm

DARE

Daré Bioscience announced the publication of findings from the Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in The Journal of Sexual Medicine. The study supports the use of either 1-month or 24-hour recall patient-reported outcome instruments for assessing treatment efficacy, which may improve data collection compliance.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:22 pm

BIVI

BioVie Inc. (NASDAQ:BIVI) will present clinical data on Bezisterim at the 11th Aging Research and Drug Discovery Meeting in Copenhagen, Denmark, from August 26-30, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:21 pm

AKTS

Akoustis Technologies, Inc. (NASDAQ: AKTS) has received an additional $13 million purchase order for its XBAW RF filters from an existing Tier-1 customer, raising total production commitments to over $21 million. The customer also has the option to increase order quantities based on demand.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:20 pm